Axsome Therapeutics, Inc. (AXSM) Stock Price & How to Invest

Axsome Therapeutics is a US-listed (Nasdaq: AXSM) central nervous system biopharmaceutical company built around approved products and a late-stage pipeline. Its flagship is Auvelity (dextromethorphan-bupropion), an oral NMDA-receptor modulator for major depressive disorder that has become the primary growth engine, plus Sunosi (solriamfetol) for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, and Symbravo (meloxicam-rizatriptan) for acute migraine. The pipeline includes AXS-12 (reboxetine) filed with the FDA for cataplexy in narcolepsy, and earlier-stage assets such as AXS-20 (balipodect), a PDE10A inhibitor for schizophrenia and Tourette syndrome.

The investment picture is a classic commercial-ramp CNS story. Revenue is growing quickly (Q1 2026 net product revenue of ~$191M, up ~57% year over year), yet the company still posts net losses as it invests heavily in sales, marketing, and R&D. The market has assigned a large-cap-style valuation (~$12B+) that prices in continued Auvelity expansion, including a new approval for agitation associated with Alzheimer's dementia and management's stated multi-billion-dollar peak-sales ambition. That makes the stock sensitive to launch execution, label breadth, and pipeline outcomes rather than to any current profit.

Axsome remains unprofitable, reporting a Q1 2026 net loss of roughly $64.5M (about $1.26 per share), so the equity depends on future growth rather than current earnings. Revenue is heavily concentrated in Auvelity, meaning any slowdown in that launch, payer pushback, or competitive entry would weigh heavily. Cash of about $305M at March 31, 2026 against ongoing losses raises the possibility of future capital needs or dilution. Pipeline and regulatory outcomes are binary and can move the stock sharply, and eventual patent or generic competition across CNS categories is a longer-term overhang. The valuation prices in substantial execution, leaving limited margin for disappointment.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Axsome Therapeutics, Inc.'s investor relations page or your broker.

• Market cap: ~$12.4B
• Revenue (Q1 2026): ~$191M (up ~57% YoY)
• Auvelity net sales (Q1 2026): ~$153M (up ~59% YoY)
• Sunosi net revenue (Q1 2026): ~$34M (up ~34% YoY)
• Net loss (Q1 2026): ~$(64.5)M, or ~$(1.26)/share
• Cash & equivalents: ~$305M (Mar 31, 2026)

AXSM trades at a large-cap valuation despite still running net losses, so the multiple reflects expected growth and pipeline optionality rather than current profitability. The key figures to watch are Auvelity's quarterly sales trajectory and the path toward operating breakeven. Analysts broadly rate the stock favorably, but published targets vary widely and are not guarantees.

There are three common ways to get AXSM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so AXSM sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where AXSM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

AXSM is a high-growth, still-unprofitable CNS drugmaker where the case rests on Auvelity's revenue ramp and pipeline read-outs, not current earnings.

Whether AXSM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AXSM a buy?, and where the stock could go from here in the AXSM stock forecast.

For income investors, whether AXSM pays a dividend and how the payout looks is covered in does AXSM pay a dividend?